Study of the BioRISE Biolimus Drug-Coated Balloon Versus the SELUTION SLR Sirolimus-Coated Balloon in De Novo Coronary Lesions, With a Single-Arm In-Stent Restenosis Cohort (SUNRISE)
Key facts
- Who runs it
- Biosensors Europe SA
- Where
- United Kingdom2 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Not yet recruiting
- Phase
- Early phase 1
- People taking part
- 443 people, planned
- Starts
- 1 Mar 2027
- Expected to end
- 31 Mar 2031
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Biolimus A9 Drug Coated Balloon
- SELUTION SLR
- Record updated
- 16 November 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 19 criteriaShow less
Who can take part
- General (all patients):; Age ≥ 18 years
Who cannot take part
- General (all patients):; Age ≥ 18 years; Documented angina and/or a positive functional ischaemia test, unstable angina, or a stabilized NSTEMI presentation. Patients undergoing index PCI of a non-culprit lesion after AMI may be included in the absence of further documented ischaemia/angina; Female subjects of childbearing potential have a negative pregnancy test ≤ 7 days before the procedure or are using a contraceptive device or drug; Eligible for and willing to comply with dual antiplatelet therapy (DAPT); Life expectancy > 1 year; Written informed consent obtained from the subject; Willing to comply with all protocol-required follow-up visits, including the 9-month angiographic follow-up; One or more target vessel (LAD, LCx or RCA) is considered to require intervention and is suitable for treatment with a drug-coated balloon; Able to tolerate 60 seconds of coronary occlusion for each target lesion; Reference vessel diameter (RVD) ≥ 1.50 mm and ≤ 4.00 mm by visual estimation; All target lesions: baseline diameter stenosis > 50% and < 100% with distal flow of at least TIMI 2. For angiographically intermediate lesions where the indication for PCI is uncertain, lesion-specific evidence of ischaemia is demonstrated by an accepted physiological assessment (e.g. FFR, iFR or validated angiography-derived physiology) at baseline; De Novo Cohort (Randomised):; A single de novo target lesion; Target lesion length ≤ 36 mm by visual estimation; In the operator's judgement, the likelihood of requiring provisional/bail-out stenting is < 30% for each randomised target lesion; Successful lesion predilatation/preparation prior to study DCB delivery: TIMI 3 flow, residual diameter stenosis < 30%, and no flow-limiting or vessel-threatening dissection requiring further treatment or bail-out stenting; ISR Cohort (Single-Arm, BioRISE only):; Prior drug-eluting stent (DES) implantation with documented in-stent restenosis (≥ 50% diameter stenosis); ISR within a single stent layer is permitted. A focal region containing two overlapping stent layers is permitted. ISR involving three or more stent layers is not allowed; ISR occurring ≥ 1 month after the original stent implantation; Successful predilatation/preparation: TIMI 3 flow, residual diameter stenosis < 30%; No acute myocardial infarction within 72 hours of the index procedure (per ARC-DCB ISR definition)
- Chronic NYHA class III or IV heart failure prior to index PCI
- Planned major surgery within one month following the index procedure
- Currently participating in another investigational device or drug study including PMCFs
- Any previous PCI (stenting or balloon angioplasty) of the study target vessel, including in-stent restenosis at the target site (such ISR lesions may be eligible for the single-arm ISR cohort)
- Known allergy or contraindication to Biolimus, sirolimus or other limus analogues or to the coating excipients, to required antiplatelet/anticoagulant therapy, or to contrast media that cannot be adequately pre-medicated
- Definite or suspected clinically manifest active systemic infection (including clinically manifest COVID-19) at the time of the index procedure
- Known LVEF < 30% prior to index PCI
- Renal insufficiency (serum creatinine ≥ 2.0 mg/dL) or dialysis
- General all patients:
- Presentation with STEMI
- Presentation with NSTEMI with ongoing chest pain or haemodynamic instability
- Killip class III (pulmonary oedema) or IV (cardiogenic shock) at presentation
- Study target lesion located in the left main stem or in any arterial or venous bypass graft
- Pregnant, breast-feeding, or planning pregnancy during the study period
- Subject is unable to comply fully with the study protocol
- Subject is under judicial protection, tutorship or curatorship (France only, if selected); De Novo Cohort (Randomised) - additional:
- Chronic total occlusion (CTO; TIMI flow 0) of a study target lesion
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Coronary heart disease causes narrowing of the heart (coronary) arteries (arteries are blood vessels, which supply oxygen-rich blood to the heart muscle). Your heart specialist will have explained to you that they suspect that you have a narrowing in one or more of your heart arteries. This narrowing may be causing you to have chest pains or evidence of reduced blood supply to your heart muscle.
Read full original descriptionShow less
One commonly used treatment for this problem is to stretch the narrowing with a balloon and then insert a small mesh-like device called a stent, which will hold the artery open, improving the blood flow to your heart, and thereby help with your symptoms. An alternative treatment is to open the narrowing with a balloon that is coated with an anti-inflammatory drug (so called drug-coated balloon) as treatment instead of a stent. Drug-coated balloons are used to reduce the risk of re-narrowing of your coronary arteries without leaving an implant (like a stent) behind. A stent (which is a foreign object that does not belong in the body) can cause vessel inflammation and it bears the risk of blockage within the stent (in-stent restenosis or ISR). Drug-coated balloons leave no implant behind but target the narrowing in your vessel wall with the delivery of an anti-inflammatory agent to the vessel wall, allowing the blood vessel to heal.
Biosensors has developed a balloon coated with a drug called Biolimus A9™ which suppresses inflammation in the artery where the narrowing has occurred. We refer to this balloon coated with Biolimus A9™ as BA9-DCB (Biolimus A9™ drug-coated balloon) also known as BioRISE. This device is not commercially available and will be tested in this study for the first time in humans. However, several coronary stents made by Biosensors are already on the market that contain the Biolimus A9™ drug. It has been proven to be safe and effective in preventing re-narrowing of the artery where the stent is placed.
In this study, two types of drug-coated balloons (DCBs) will be used; the BioRISE (test group; group 1) and SELUTION SLR, a balloon that is coated with sirolimus (control group; group 2). The SELUTION SLR balloon is commercially available in Europe.
The study has the following design:
• Patients will be treated according to standard hospital procedures using the study device.
The study has the following design:
* Patients will be treated according to standard hospital procedures using the study device. * There will be two different types of patients included in this study. * 400 patients with a narrowing in a heart artery that has never been treated before (referred to as de novo disease), of whom 200 will be treated with the BioRISE balloon and 200 with the SELUTION SLR balloon. The allocation to the two possible treatments is random as it must be in a study like this. Of these 400 patients, 15 in each treatment arm, will have the inside of the artery imaged during the procedure using a well-established technique called Optical Coherence Tomography (OCT) and Quantitative Flow Ratio (QFR) * 43 patients with a narrowing inside a stent that was implanted in the past (referred to as in-stent restenosis). In these patients, only the BioRISE balloon will be used. * Your doctor will explain to which category applies to you. * There will be up to 25 hospitals taking part in the study in the UK, and in up to 5 European countries * Patients will be taking part in the study for up to 3 years, and during this time their health status will be assessed by telephone or hospital visit at 1month, 9 month, 12 months, 24 months and 36 months. * There will be a check up angiography to assess the primary end point at 9 months for all participants.
The 2 groups in the trial
- BioRISE Biolimus Drug-Coated BalloonTreatment being tested
BioRISE is a semi-compliant, rapid-exchange (RX) percutaneous transluminal coronary angioplasty (PTCA) balloon catheter built on the CE-marked RISE™ SC catheter platform with modified hypotube, compatible with a 0.014" guidewire. The device leaves no permanent implant, the only residual is the transferred drug.
Treatment: Biolimus A9 Drug Coated Balloon
- SELUTION SLR sirolimus-coated balloonExisting treatment, for comparison
SELUTION SLR (Cordis / MedAlliance), a sirolimus-coated drug-coated balloon on a 0.014" rapid-exchange PTCA platform, CE-marked and used within its approved intended purpose.
Treatment: SELUTION SLR
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Prospective, Randomised, Multicenter, Single-Blind Non-Inferiority Study of the BioRISE Biolimus Drug-Coated Balloon Versus the SELUTION SLR Sirolimus-Coated Balloon in De Novo Coronary Lesions, With a Single-Arm In-Stent Restenosis Cohort (SUNRISE)
- Record updated
- 16 November 2026